Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YWHAH | Q04917 | 1/20 | 0.47 |
| ▸ | EDNRB | P24530 | 8/20 | 0.47 |
| ▸ | EDNRA | P25101 | 6/20 | 0.47 |
| ▸ | CD74 | P04233 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 3/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6859336 | 0.76 | PPARG (0.54) | EDNRBEDNRACD74MIFTP53 | |
| SCHEMBL8553492 | 0.75 | EDNRB (0.64) | EDNRBEDNRATP53PPARGPTGES | |
| SCHEMBL4591747 | 0.73 | EDNRB (0.61) | EDNRBEDNRATP53 | |
| SCHEMBL8551194 | 0.73 | EDNRB (0.64) | EDNRBEDNRATP53POLBPTGES | |
| SCHEMBL8549014 | 0.73 | EDNRB (0.61) | EDNRBEDNRAPPARG | |
| SCHEMBL7176922 | 0.72 | EDNRB (0.42) | EDNRBEDNRATP53POLB | |
| SCHEMBL6858382 | 0.72 | PPARG (0.76) | EDNRBEDNRAPOLBPPARGPTGES | |
| SCHEMBL8553006 | 0.70 | EDNRB (0.62) | EDNRBEDNRAPLA2G2A | |
| SCHEMBL6091159 | 0.69 | PPARG (0.65) | EDNRBEDNRAPPARGPTGES | |
| SCHEMBL8902335 | 0.69 | EDNRB (0.80) | EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | YWHAH 1248/4885EDNRB 170/4885EDNRA 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.